Disturbance In The Composition of Lipoprotein Particles And Chronic Inflammation As Prognostic Factors In The Development of Coronary Disease
The study focused on 30 dyslipidemic patients (12 women and 18 men); 16 of them had coronary disease (CD). The concentrations of apoA and apoB were determined in all patients, as well as the calculated ratio between apoA and apoB. As far as inflammatory indicators are concerned, the concentrations of sensitive C reactive protein (hsCRP), albumin, fibrinogen, intracellular adhesive molecule (ICAM-1) and vascular adhesive molecule (VCAM -1) were determined. In patients with CD there were considerably higher concentrations of fibrinogen (3.1 ± 1.2 vs. 2.7 ± 0.7 g/L) and VCAM-1 (10.9 ± 3.6 vs. 8.3 ± 2.8 g/L) (p<0.05) while the numerical values of hsCRP and ICAM-1 were not significantly different in relation to the patients without CD. The concentration of apoB and the value of apoB/apoA ratio were considerably higher in patients with CD (1.7 ± 0.8 vs. 1.3 ± 0.4 and 1.3 ± 0.4 vs. 0.9 ± 0.4; p<0.05), whereas the concentration of apoA did not differ in relation to the patients without CD. The research confirmed the significance of the disturbance in the composition of lipoprotein particles and the systemic inflammatory response in the pathogenesis of atherosclerosis, whereas their significant mutual connection was not shown. This indicates their cumulative effect and different mechanisms at the base of these disturbances.
If the inline PDF is not rendering correctly, you can download the PDF file here.
Ostojić M Vukčević V Dimković S et al. Novine u prevenciji ishemijske bolesti srca. Balneoclimatologia 2003; 27: 69-81.
Ilić S. Efekti simvastatina u prevenciji koronarne bolesti. In: Savić T ed. et al. Evaluacija dijagnostika i terapija dislipidemija. Zbornik radova Dislipidemija i ateroskleroza I ed; 2003 Maj 5-7; Niš: Punta; 2003; 334-43.
Gotto AM Pownall HJ. Manual of lipid disorders. Reducing the risk for coronary heart disease. Philadelphia: Lippincott Williams and Wilkins 2003.
Đinđić B. Dejstvo antilipemične terapije na patogenezu ateroskleroze kod bolesnika sa dijabetesom. Medical Faculty Niš 2006.
Sniderman AD Scantlebury T Cianflone K. Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 2001 135: 447-59.
Tkac I Mudrykova T Szabo E Durovcova E Lewis GF. Carotid intima-media thickness in type 2 diabetes is more strongly related to serum apoprotein A-I in females. Wien Klin Wochenschr 2001; 113: 194-8.
Walldius G Jungner I Holme I Aastveit AH Kolar W Steiner E. High apolipoprotein B low apolipoprotein A-I and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001 358: 2026-33.
Maseri A. Inflammation atherosclerosis and ischemic events - exploring the hidden side of moon. N Eng J Med 1997; 336: 1014-16.
Gurau U Erbaz AR Guraz Z Zilmaz BM Bozac AA Sasmaz H et al. Levels of soluble adhesion molecules in various clinical presenation of coronary atherosclerosis. Int J Cardiol 2003; 89: 53-62.
Nissen SE Tuzcu EM Schoenhagen P Crowe T Sasiela WJ Tsai J et al. Statin therapy LDL-C C-reactive protein and coronary artery disease. N Engl J Med 2005; 352: 29-38.
Đinđić B Damnjanović G Mitrović V Sokolović D. Dijabetesna dislipidemija i ateroskleroza. Vojnosanitetski Pregled 2004; 61 (1): 71-5.
Leinonen M Saikku P. Evidence for infectious agents in cardiovascular disease and atherosclerosis. The Lancent Infectious Diseases 2002; 2: 15-29.
Tiong A Brieger D. Inflammation and coronary artery disease. Am Heart J 2005; 150: 11-8.
Ridker P Brown N Vaughan D et al. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004; 109 (Suppl): 6-19.
Blake G Ridker P. Inflammatory biomarkers and cardiovascular risk prediction. J Intern Med 2002; 252: 283-94.